OPELLA
Acquired by
CLAYTON, DUBILIER & RICE (CD&R)
OPELLA acquired by CLAYTON, DUBILIER & RICE (CD&R)
Target
OPELLA
Acquirer
CLAYTON, DUBILIER & RICE (CD&R)
Context
Sanofi has announced the sale of 50% of its stake in Opella to the American fund CD&R. Opella Healthcare (formerly Sanofi Consumer Healthcare) is a company specializing in consumer healthcare products.
OPELLA, which reported an EBITDA margin of LOGIN in 2025, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN premium to the 13.4x average currently observed in the Healthcare & Pharma sector.
Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
Opella is a global leader in consumer healthcare, managing a portfolio of iconic brands such as Doliprane, Allegra, Dulcolax, and Mucosolvan. It operates in 100 countries and focuses on over-the-counter (OTC) medicines, vitamins, and supplements.
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples Analysis
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Other operations with OPELLA
mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.